Polen Capital Management LLC Boosts Holdings in Repligen Co. (NASDAQ:RGEN)

Polen Capital Management LLC increased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 14.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 40,556 shares of the biotechnology company's stock after acquiring an additional 5,173 shares during the quarter. Polen Capital Management LLC owned about 0.07% of Repligen worth $5,838,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Champlain Investment Partners LLC boosted its position in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock valued at $211,464,000 after acquiring an additional 850,345 shares during the period. Conestoga Capital Advisors LLC boosted its position in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after acquiring an additional 6,872 shares during the period. Thrivent Financial for Lutherans raised its stake in Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock valued at $95,037,000 after purchasing an additional 36,773 shares in the last quarter. DF Dent & Co. Inc. raised its stake in Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock valued at $87,852,000 after purchasing an additional 139,615 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in Repligen by 2.5% in the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock valued at $83,693,000 after purchasing an additional 14,398 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of the company's stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on RGEN shares. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. Royal Bank of Canada raised their target price on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. raised their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $178.64.

Repligen Trading Down 3.8 %

NASDAQ:RGEN traded down $5.54 during trading hours on Thursday, hitting $139.34. The company had a trading volume of 445,053 shares, compared to its average volume of 648,733. The company has a market capitalization of $7.81 billion, a PE ratio of -273.22, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The stock has a 50-day moving average price of $156.78 and a 200 day moving average price of $148.46. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $200.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, equities research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.